Indazole, benzisoxazole, and benzisothiazole kinase inhibitors

A compound of formula (I)

• or a therapeutically acceptable salt thereof, wherein
• A is phenyl;
• X is NR9;
• one of R1 and R2 is hydrogen and the other is selected from the group consisting of aryloxyalkyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkoxy, heterocyclylalkyl, heterocyclyloxyalkyl, (NRaRb)alkoxy, (NRaRb)alkenyl, (NRaRb)alkyl, (NRaRb)alkynyl, (NRaRb)carbonylalkenyl, and (NRaRb)carbonylalkyl;
• R3 and R4 are each independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkyl, halo, haloalkoxy, haloalkyl, and hydroxy;
• R5 is LR6;
• L is selected from the group consisting of (CH2)mN(R7)C(O)N(R8)(CH2)n and CH2C(O)NR7, wherein m is 0 and n is 0, and wherein each group is drawn with its left end attached to A;
• R6 is selected from the group consisting of hydrogen, aryl, cycloalkyl, heterocyclyl, and 1,3-benzodioxolyl wherein the 1,3-benzodioxolyl can be optionally substituted with one, two, or three substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, aryl, arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, cycloalkyl, halo, haloalkoxy, haloalkyl, a second heterocyclyl group, heterocyclylalkyl, hydroxy, hydroxyalkyl, nitro, —NRcRd, and (NRcRd)alkyl;
• R7 and R8 are independently selected from the group consisting of hydrogen and alkyl;
• R9 is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkylcarbonyl, aryl, heterocyclylalkyl, hydroxyalkyl, and (NRaRb)alkyl;
• Ra and Rb are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylcarbonyl, arylsulfonyl, haloalkylsulfonyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, and heterocyclylsulfonyl;
• and
• Rc and Rd are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl and heterocyclyl.